ANAPC1P2

Across TCGA pan-cancer cohorts, ANAPC1P2 Mutation is linked to patient survival in 2 of 34 cancer types, making it a survival-associated ANAPC1P2 data layer compared with 21 for mass-spec protein.

The strongest signal is observed in adrenocortical carcinoma (ACC), where higher ANAPC1P2 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated ANAPC1P2 expression acts as an unfavorable survival marker.

ACC and SKCM are the cancer types where ANAPC1P2 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
ACC	DFS	Median	All	0.089	0.666	.017	6	view →
SKCM	DFS	Median	All	0.201	0.615	.005	6	view →

Pink = unfavorable, green = favorable. Showing the 2 strongest of 2 lineages.

ANAPC1P2–ACC (DFS)

Open the ACC breakdown →